Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients. (23rd June 2020)

• Record Type: Journal Article
• Authors: Olearo, Flaminia; Kronig, Ilona; Masouridi-Levrat, Stavroula; Chalandon, Yves; Khanna, Nina; Passweg, Jakob; Medinger, Michael; Mueller, Nicolas J; Schanz, Urs; Van Delden, Christian; Neofytos, Dionysios
• Is Part Of: Open forum infectious diseases. Volume 7:Number 7(2020)
• Publication Date: 2020-06-23
• Subjects: allogeneic hematopoietic cell transplant recipients -- duration treatment -- Pseudomonas aeruginosa -- recurrent infection; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofaa246
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: In a large, multicenter, contemporary, 8-year, cohort study, one third of allogeneic-hematopoietic cell transplant (HCT) recipients with Pseudomonas aeruginosa (PSA) infection developed a recurrent infection within 3 months. Antibiotic treatment duration of ≥14 days was the only significantly associated variable with reduced recurrence rates of PSA infections in allogeneic-HCT recipients. Abstract : In a large retrospective multicenter 8-year cohort study, Pseudomonas aeruginosa (PSA)-infections in allogeneic hematopoietic cell transplant recipients were associated with 30% recurrence rate. A minimum of 14-day antibiotic treatment was required in order to prevent recurrent PSA-infections.?